In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.
|Published (Last):||4 December 2006|
|PDF File Size:||17.47 Mb|
|ePub File Size:||13.21 Mb|
|Price:||Free* [*Free Regsitration Required]|
Concurrent medications whose metabolism could be affected by VKAs; 9. N Engl J Med ; AVERROES on the other averfoes has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. Connolly SJ, et al. VKA therapy not recommended by the physician; With a mean follow-up of 1. Mortality rates were 3. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.
AVERROES – Wiki Journal Club
Yet, these proportions reflect the current underuse of VKAs in multiple registries. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Patients were eligible if they avverroes 50 years of age or older and if they had atrial fibrillation that had been documented in the 6 months prior to enrollment or by lead electrocardiography on the day of screening. Sign in to My ESC. There were avedroes primary outcome events in those randomised to apixaban 1.
Analyses are to time of first event. Expected difficulty in contacting patient for urgent change in dose of VKAs; 6.
The AVERROES Trial – Clinical Implications
Read your latest personalised notifications Sign in No account yet? The New England Journal of Medicine. All these reasons can be grouped in three broad categories: Other characteristics indicating risk of stroke too low to warrant treatment with VKAs; In addition, patients could not be receiving VKA therapy, either because it had been demonstrated unsuitable in their case or because it was expected to be unsuitable. In such patients, aspirin plus clopidogrel reduced the rate of major vascular events, in particular stroke, vs.
Notes to editor Correspondence: Strengths Strong points and important messages of the study are: To get the best experience using our website we recommend that you upgrade to a newer version. The primary outcome was stroke or systemic embolism.
ESC sub specialties communities. It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug interactions. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: Assessment that INR could not or was unlikely to be measured at requested interval; 5.
The reasons that VKA therapy was unsuitable for the patient had to be documented in the study case report forms. Thus, a clear superiority of apixaban over aspirin was shown in terms of efficacy, with comparable safety.
Views Read View source View history. One may question each of these choices: Dual therapy decreased rates of major vascular events at cost of increased major bleeding. Dabigatran versus warfarin in patients with atrial fibrillation. Did you know that your browser is out of date? A serious bleeding event during VKA therapy; 4.
The AVERROES Trial – Clinical Implications
Patients also needed to have at least one of the following risk factors for stroke: Statistics presented where given by the authors. Assessment that patient would be unable or unlikely to adhere to restrictions on factors such as alcohol and diet; Based on the indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs.
Eur Heart J ; In patients with atrial fibrillation thought to be unsuitable for anticoagulation with a vitamin K antagonist, does apixaban reduce risk for stroke or systemic embolism when compared to aspirin?
In April the Data and Safety Monitoring Board recommended early study termination because of clear benefit in favor of apixaban. The median duration of follow-up was 1. Its role in prevention of stroke in patients unsuitable for VKA therapy, but maintained on aspirin therapy, was unknown.
There were 44 1.
Presented as apixaban vs. Apixaban in Patients with Atrial Fibrillation. Also, how does apixaban compare to aspirin rates of major bleeding? Navigation menu Personal tools Create account Log in.